Respiratory syncytial virus (RSV) is an important cause of
acute lower respiratory tract disease in infants, young children,
immunocompromised individuals, and the elderly. However,
despite ongoing efforts to develop an RSV vaccine, there
is still no authorized RSV vaccine for humans. Baculovirus
has attracted attention as a vaccine vector because of its ability
to induce a high level of humoral and cellular immunity, low
cytotoxicity against various antigens, and biological safety
for humans. In this study, we constructed a recombinant baculovirus-
based vaccine expressing the M2 protein of RSV under
the control of cytomegalovirus promoter (Bac_RSVM2)
to induce CD8+ T-cell responses which play an important
role in viral clearance, and investigated its protective efficacy
against RSV infection. Immunization with Bac_RSVM2 via
intranasal or intramuscular route effectively elicited the specific
CD8+ T-cell responses. Most notably, immunization with
Bac_RSVM2 vaccine almost completely protected mice from
RSV challenge without vaccine-enhanced immunopathology.
In conclusion, these results suggest that Bac_RSVM2 vaccine
employing the baculovirus delivery platform has promising
potential to be developed as a safe and novel RSV vaccine
that provides protection against RSV infection.
Citations
Citations to this article as recorded by
Respiratory delivered vaccines: Current status and perspectives in rational formulation design Lan Wu, Wenwen Xu, Huiyang Jiang, Mingshi Yang, Dongmei Cun Acta Pharmaceutica Sinica B.2024; 14(12): 5132. CrossRef
Enhanced virulence of genetically engineered Autographa californica nucleopolyhedrovirus owing to accelerated viral DNA replication aided by inserted ascovirus genes Huan Yu, Chang-Jin Yang, Yi-Yi Ou-Yang, Yue Tong, Hui-Yu Lan, Jia-Min Gan, Shi-Wei Li, Ding-Yi Bai, Guo-Hua Huang Pesticide Biochemistry and Physiology.2023; 192: 105382. CrossRef
Cytokines and CD8 T cell immunity during respiratory syncytial virus infection Megan E. Schmidt, Steven M. Varga Cytokine.2020; 133: 154481. CrossRef
Induction of mucosal immunity against pathogens by using recombinant baculoviral vectors: Mechanisms, advantages, and limitations Mario Fragoso-Saavedra, Marco A Vega-López Journal of Leukocyte Biology.2020; 108(3): 835. CrossRef
Endogenous n-3 Polyunsaturated Fatty Acids Are Beneficial to Dampen CD8+ T Cell-Mediated Inflammatory Response upon the Viral Infection in Mice Kyung Won Kang, Seyoung Kim, Yong-Bin Cho, Seung Rok Ryu, Young-Jin Seo, Sang-Myeong Lee International Journal of Molecular Sciences.2019; 20(18): 4510. CrossRef
Anti-viral activity of compounds from Agrimonia pilosa and Galla rhois extract mixture Jeong Eun Kwon, Yeong-Geun Lee, Ji-Hun Kang, Yun-Feng Bai, Yong Joon Jeong, Nam-In Baek, Young-Jin Seo, Se Chan Kang Bioorganic Chemistry.2019; 93: 103320. CrossRef
Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus Yeong-Min Jo, Jungwoo Kim, Jun Chang Clinical and Experimental Vaccine Research.2019; 8(1): 43. CrossRef
Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease Tatiana Kotomina, Irina Isakova-Sivak, Victoria Matyushenko, Ki-Hye Kim, Youri Lee, Yu-Jin Jung, Sang-Moo Kang, Larisa Rudenko Antiviral Research.2019; 168: 9. CrossRef
The CD8 T Cell Response to Respiratory Virus Infections Megan E. Schmidt, Steven M. Varga Frontiers in Immunology.2018;[Epub] CrossRef